Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Trial of Sorafenib (CRAF, BRAF, KIT, RET, VEGFR, PDGFR Inhibitor) or Crizotinib (MET, ALK, ROS1 inhibitor) in Combination with Vemurafenib (BRAF Inhibitor) in Patients with Advanced Malignancies

Next Previous
X
Search
Trial Profile

A Phase I Trial of Sorafenib (CRAF, BRAF, KIT, RET, VEGFR, PDGFR Inhibitor) or Crizotinib (MET, ALK, ROS1 inhibitor) in Combination with Vemurafenib (BRAF Inhibitor) in Patients with Advanced Malignancies

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 07 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Crizotinib (Primary) ; Sorafenib (Primary) ; Vemurafenib (Primary)
  • Indications Adenocarcinoma; Cancer; Colorectal cancer; Lung cancer; Malignant melanoma; Neuroendocrine carcinoma; Non-small cell lung cancer; Ovarian cancer; Seminoma; Thyroid cancer
  • Focus Adverse reactions

    • Most Recent Events

    • 19 Jan 2021 Status changed from active, no longer recruiting to completed.
    • 29 Oct 2020 Protocol was revised to consider patients who received at least 80% of the planned doses to be evaluable for DLT.
    • 29 Oct 2020 Results published in the Cancer

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top